Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HealOr Ltd.

www.healor.com

Latest From Ovalis Inc.

Recent Developments in PFO Closure

The patent foramen ovale closure market has continued to mature in 2009, with the latest round of developments reported at the 2009 Transcatheter Cardiovascular Therapeutics meeting, recently held in San Francisco. Over 60 presentations related to PFO closure or atrial septal defect closure were presented at TCT this year, more than double the amount of PFO-related talks presented in 2008.
Medical Device

Migraine: Can Devices Spell Relief

As many as half of severe migraine sufferers do not achieve adequate relief with prescription drug therapy, and many of these patients may be candidates for emerging device treatments for migraine. Sales of migraine drugs in the U.S. total more than $2 billion per year, but some analysts believe that the potential market for device-based treatment may be even larger. The question at the moment is whether the devices in development can produce the kind of results that migraine patients are looking for. Clinical trials are currently underway on a number of fronts, and based on early data, the answer looks promising.
Medical Device Clinical Trials

Cierra Inc.

Following on the pioneering work of NMT Medical and AGA Medical, Cierra has come onto the scene with a completely new way to close the PFO (a congenital opening in the heart that can cause stroke and migraine). Diverging from the implant developers that came before, Cierra has a device-based approach for migraine that leaves nothing behind in the body.
Medical Device Platform Technologies

Ovalis' Reverse Spin

Most small companies grow for a while and then sell off to a larger acquiror. Ovalis, an intriguing start-up in the PFO space, has reversed the process, beginning as part of Abbott Laboratories' Abbott Vascular Division before being spun off as an independent company.
Medical Device Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • HealOr Ltd.
  • Senior Management
  • Michael L Sabolinski, MD, CEO
    Haim Bar Zik, CFO
    Liora Braiman-Wiksman, PhD, VP, R&D
    Revital Mandil-Levin, Head, Bus. Dev.
  • Contact Info
  • HealOr Ltd.
    Phone: (972) 8 9407188
    3 Prof. Chaim Pekeris St.
    Floor 5
    P.O. Box 4115 Rechovot, 76702
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register